-
1
-
-
0022647432
-
The product of the human c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
-
3012781 10.1126/science.3012781
-
Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644-1646
-
(1986)
Science
, vol.232
, pp. 1644-1646
-
-
Akiyama, T.1
Sudo, C.2
Ogawara, H.3
Toyoshima, K.4
Yamamoto, T.5
-
2
-
-
0022399581
-
Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
-
2999974 10.1126/science.2999974
-
Coussens L, Yang-Feng TL, Liao YC et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132-1139
-
(1985)
Science
, vol.230
, pp. 1132-1139
-
-
Coussens, L.1
Yang-Feng, T.L.2
Liao, Y.C.3
-
3
-
-
50849123421
-
HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target
-
18441328 10.1093/annonc/mdn169
-
Gravalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529
-
(2008)
Ann Oncol
, vol.19
, pp. 1523-1529
-
-
Gravalos, C.1
Jimeno, A.2
-
4
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
3798106 10.1126/science.3798106
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.J.4
Ullrich, A.5
McGuire, W.L.6
-
5
-
-
20044372721
-
Amplification of HER-2 in gastric carcinoma: Association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
-
15668283 10.1093/annonc/mdi064
-
Tanner M, Hollmén M, Junttila TT et al (2005) Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16:273-278
-
(2005)
Ann Oncol
, vol.16
, pp. 273-278
-
-
Tanner, M.1
Hollmén, M.2
Junttila, T.T.3
-
6
-
-
44249092320
-
Assessment of a HER2 scoring system for gastric cancer: Results from a validation study
-
18422971 10.1111/j.1365-2559.2008.03028.x
-
Hofmann M, Stoss O, Shi D et al (2008) Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52:797-805
-
(2008)
Histopathology
, vol.52
, pp. 797-805
-
-
Hofmann, M.1
Stoss, O.2
Shi, D.3
-
7
-
-
77956262693
-
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
-
ToGA Trial Investigators et al. 20728210 10.1016/S0140-6736(10)61121-X
-
Bang YJ, van Cutsem E, Feyereislova A, ToGA Trial Investigators et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687-697
-
(2010)
Lancet
, vol.376
, pp. 687-697
-
-
Bang, Y.J.1
Van Cutsem, E.2
Feyereislova, A.3
-
8
-
-
0034954242
-
Assessment of actual significance levels for covariate effects in NONMEM
-
11468939 10.1023/A:1011527125570
-
Wählby U, Jonsson EN, Karlsson MO (2001) Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28:231-252
-
(2001)
J Pharmacokinet Pharmacodyn
, vol.28
, pp. 231-252
-
-
Wählby, U.1
Jonsson, E.N.2
Karlsson, M.O.3
-
9
-
-
75149145545
-
Pharmacokinetics and pharmacodynamics of monoclonal antibodies: Concepts and lessons for drug development
-
20055530 10.2165/11530560-000000000-00000
-
Mould DR, Green B (2010) Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs 24:23-39
-
(2010)
BioDrugs
, vol.24
, pp. 23-39
-
-
Mould, D.R.1
Green, B.2
-
10
-
-
77956388219
-
Population pharmacokinetics of therapeutic monoclonal antibodies
-
20818831 10.2165/11535960-000000000-00000
-
Dirks NL, Meibohm B (2010) Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 49:633-659
-
(2010)
Clin Pharmacokinet
, vol.49
, pp. 633-659
-
-
Dirks, N.L.1
Meibohm, B.2
-
11
-
-
78049485263
-
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
-
21351269 10.1002/ijc.25516
-
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917
-
(2010)
Int J Cancer
, vol.127
, pp. 2893-2917
-
-
Ferlay, J.1
Shin, H.R.2
Bray, F.3
Forman, D.4
Mathers, C.5
Parkin, D.M.6
-
12
-
-
79952232216
-
Global cancer statistics
-
21296855 10.3322/caac.20107
-
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
-
(2011)
CA Cancer J Clin
, vol.61
, pp. 69-90
-
-
Jemal, A.1
Bray, F.2
Center, M.M.3
Ferlay, J.4
Ward, E.5
Forman, D.6
-
13
-
-
14944385553
-
Global cancer statistics, 2002
-
15761078 10.3322/canjclin.55.2.74
-
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
-
(2005)
CA Cancer J Clin
, vol.55
, pp. 74-108
-
-
Parkin, D.M.1
Bray, F.2
Ferlay, J.3
Pisani, P.4
-
14
-
-
0029160004
-
Effective half-life in clinical pharmacology
-
8522631 10.1002/j.1552-4604.1995.tb04117.x
-
Boxenbaum H, Battle M (1995) Effective half-life in clinical pharmacology. J Clin Pharmacol 35:763-766
-
(1995)
J Clin Pharmacol
, vol.35
, pp. 763-766
-
-
Boxenbaum, H.1
Battle, M.2
-
15
-
-
84877865099
-
The combination of exposure-response and case-control analyses in regulatory decision making
-
23436261 10.1177/0091270012445206
-
Yang J, Zhao H, Garnett C et al (2013) The combination of exposure-response and case-control analyses in regulatory decision making. J Clin Pharmacol 53:160-166
-
(2013)
J Clin Pharmacol
, vol.53
, pp. 160-166
-
-
Yang, J.1
Zhao, H.2
Garnett, C.3
-
16
-
-
32444438731
-
Elimination mechanisms of therapeutic monoclonal antibodies
-
16478695 10.1016/S1359-6446(05)03638-X
-
Tabrizi MA, Tseng CM, Roskos LK (2006) Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 11:81-88
-
(2006)
Drug Discov Today
, vol.11
, pp. 81-88
-
-
Tabrizi, M.A.1
Tseng, C.M.2
Roskos, L.K.3
-
17
-
-
4143050397
-
Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer
-
15210739 10.1200/JCO.2004.11.061
-
Rowinsky EK, Schwartz GH, Gollob JA et al (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22:3003-3015
-
(2004)
J Clin Oncol
, vol.22
, pp. 3003-3015
-
-
Rowinsky, E.K.1
Schwartz, G.H.2
Gollob, J.A.3
-
18
-
-
84937027579
-
-
European Medicines Agency Accessed 29 Oct 2013
-
European Medicines Agency (2012) EPAR summary for the public http://www.ema.europa.eu/docs/en-GB/document-library/EPAR -Summary-for-the- public/human/000278/WC500049819.pdf Accessed 29 Oct 2013
-
(2012)
EPAR Summary for the Public
-
-
-
19
-
-
23244455101
-
Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer
-
15868146 10.1007/s00280-005-1026-z
-
Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P (2005) Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 56:361-369
-
(2005)
Cancer Chemother Pharmacol
, vol.56
, pp. 361-369
-
-
Bruno, R.1
Washington, C.B.2
Lu, J.F.3
Lieberman, G.4
Banken, L.5
Klein, P.6
-
21
-
-
78650381707
-
Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature
-
3019132 21176210 10.1186/1475-2891-9-69
-
Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69
-
(2010)
Nutr J
, vol.9
, pp. 69
-
-
Gupta, D.1
Lis, C.G.2
|